FDA Talking To Industry About Releasing “Complete Response” Letters
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Commissioner Hamburg says conversations are underway with industry to allow the agency to release its reasons for not approving a product, in part so others will not waste funds repeating known failures. FDA is also working to remove user fee revenue from sequestration.